Effect of tofacitinib combined with methotrexate on disease activity, rheumatoid factor level and morning stiffness time in patients with refractory rheumatoid arthritis / 中国医师杂志

Objective:To investigate the effect of tofacitinib combined with methotrexate on disease activity, rheumatoid factor (RF) level and morning stiffness time in patients with refractory rheumatoid arthritis (RA).Methods:A total of 120 patients with refractory RA diagnosed and treated in the First Affiliated Hospital of Hebei North University from June 2019 to June 2020 were selected as the study subjects, and they were randomly divided into three groups by random number table method: etanercept group, etanercept+ methotrexate group, and tofacitinib+ methotrexate group, with 40 patients in each group. The etanercept group was given etanercept treatment, the etanercept+ methotrexate group was given etanercept combined with methotrexate treatment, and the tofacitinib+ methotrexate group was given tofacitinib combined with methotrexate treatment. The clinical efficacy (12 W, 24 W and 48 W of treatment), disease activity, RF level, morning stiffness time and incidence of adverse reactions were compared among the three groups.Results:Comparison of the total clinical effective rate of the three groups: the total clinical effective rate of the etanercept+ methotrexate group and the tofacitinib+ methotrexate group was higher than that of the etanercept group (both P<0.05), and the tofacitinib+ methotrexate group was higher than that of the etanercept+ methotrexate group ( P<0.05). After treatment, the clinical symptoms and disease activity scores (DAS28) in the etanercept+ methotrexate and tofacitinib+ methotrexate groups were significantly improved compared with the etanercept group (all P<0.05), and the improvements in the tofacitinib+ methotrexate group were more significant than those in the etanercept+ methotrexate group ( P<0.05). After treatment, the erythrocyte sedimentation rate (ESR), RF and C-reactive protein (CRP) levels were lower in the etanercept+ methotrexate and tofacitinib+ methotrexate groups than those in the etanercept groups (all P<0.05), and the ESR, RF and CRP levels in the tofacitinib+ methotrexate groups were lower than those in the etanercept+ methotrexate group (all P<0.05). There was no significant difference in the incidence of total adverse reactions among 3 groups (7.50% vs 12.50% vs 12.50%) ( P>0.05). Conclusions:Tofacitinib combined with methotrexate can effectively improve the disease activity, RF level and morning stiffness time in patients with refractory RA, with high safety, which is worthy of clinical application and promotion.

Factor reumatoide en vasculitis ANCA asociadas / Rheumatoid factor in ANCA associated vasculitis

Introducción: las pruebas de factor reumatoide (FR) se utilizan principalmente para el diagnóstico de artritis reumatoidea (AR), sin embargo, también pueden estar presentes en otras enfermedades. Su significado clínico en contexto de vasculitis ANCA asociadas (VAA) todavía es incierto. El objetivo de este estudio fue establecer el significado clínico y pronóstico del FR en pacientes con VAA. Materiales y métodos: se realizó un estudio observacional, retrospectivo. Se evaluaron pacientes con diagnóstico de VAA (granulomatosis con poliangitis -GPA-, poliangitis microscópica -PAM- y granulomatosis eosinofílica con poliangitis -GEPA-), mayores de 18 años, con FR solicitado antes del inicio del tratamiento. Se recolectaron los siguientes datos: edad, sexo, tipo de VAA, duración de la enfermedad, tratamiento, órganos afectados, Birmingham Vasculitis Activity Score (BVAS), Five Factor Score (FFS), eritrosedimentación, proteína C reactiva, requerimiento de diálisis, asistencia respiratoria mecánica, mortalidad y causa de muerte. Se calculó el odds ratio (OR) y su intervalo de confianza del 95% (IC 95%) para determinar la fuerza de asociación entre las variables. Resultados: incluimos 32 pacientes en los que encontramos 31,2% de FR positivo. Comparados con aquellos con FR negativo, no hubo diferencias significativas con respecto a manifestaciones clínicas, ni actividad de la enfermedad medida por el BVAS y reactantes de fase aguda. La presencia de factor reumatoide se asoció a menor ingreso a diálisis (OR 0.14 IC 0,02-0,8; p=0,02) y mortalidad (p=0,04). No hubo diferencias significativas con respecto al FFS. Conclusiones: en nuestro estudio la presencia de FR en pacientes con vasculitis ANCA se asoció a menor requerimiento de diálisis y menor mortalidad. Estos hallazgos no se correlacionaron estadísticamente con el FFS. No se encontró asociación entre la presencia de FR y el compromiso de órgano, actividad de la enfermedad, ni requerimiento de asistencia respiratoria mecánica.

Introduction: rheumatoid factor tests are mainly used for the diagnosis of rheumatoid arthritis (RA); however, it may also be present in other diseases. Its clinical significance in the context of ANCA associated vasculitis (AAV) is still uncertain. The objective was to establish the clinical and prognostic significance of RF in patients with AAV. Materials and methods: a retrospective observational study was carried out. Patients with a diagnosis of AAV (GPA, MAP and AGEP) over 18 years of age with RF requested before the start of treatment were evaluated. The following data were collected: age, sex, type of AAV, disease duration, treatment, affected organs, Birmingham Vasculitis Activity Score (BVAS), Five Factor Score (FFS), erythrocyte sedimentation rate, C-reactive protein, dialysis requirement, attendance mechanical ventilation, mortality and cause of death. The odds ratio (OR) and its 95% confidence interval (95%CI) were calculated to determine the strength of association between variables. Results: we included 32 patients in whom we found 31.2% positive RF. Compared to those with negative RF, there were no significant differences with respect to clinical manifestations, nor disease activity measured by BVAS and acute phase reactants. The presence of the rheumatoid factor was associated with lower admission to dialysis (OR 0.14 CI 0.02-0.8 p=0.02) and mortality (p=0.04). There were no significant differences with respect to FFS. Conclusions: in our study, the presence of RF in patients with ANCA vasculitis was associated with a lower requirement for dialysis and lower mortality. These findings were not statistically correlated with the FFS. No association was found between the presence of RF and organ involvement, disease activity, or mechanical ventilation requirement.

Manifestações oculares da artrite reumatoide e positividade de autoanticorpos: uma revisão sistemática / Ocular manifestations of rheumatoid arthritis and autoantibodies positivity: a systematic review

Contexto: As manifestações oculares da artrite reumatoide representam cerca de 40% das manifestações extra-articulares, acarretando comprometimento da qualidade de vida. O fator reumatoide e o anticorpo contra peptídeos citrulinados cíclicos são marcadores sorológicos para diagnóstico laboratorial da doença. Objetivo: Identificar as principais manifestações oculares da artrite reumatoide e a sua relação com a positividade do fator reumatoide e anticorpo contra peptideos citrulinados cíclicos, através de uma revisão sistemática. Métodos: Uma revisão sistemática foi conduzida nas bases de dados: PubMed, Scopus, Web of Science e SciELO, até janeiro de 2018. Critérios de inclusão e exclusão foram aplicados e dados dos estudos selecionados foram extraídos e organizados em tabelas e gráficos. Avaliação metodológica e análise estatística, incluindo duas meta-análises, foram realizadas. Os estudos selecionados foram armazenados no Software Endnote X8 versão student (Serial Number: 3151802521 e Product Key: L899B-8N8FJ-SX9JW-BEQ58-U9HCD). Análises estatísticas foram realizadas com o Software Review Manager versão 5.3 (software gratuito). Resultados: Dos 1.985 estudos encontrados através da busca em bases de dados, quatro estudos foram incluídos. A síndrome sicca e síndrome de Sjögren secundária representaram cerca de 50% das manifestações oculares. Meta-análises aplicadas em dois estudos não identificaram associação de risco estatisticamente significativa entre o anticorpo contra peptideos citrulinados cíclicos e fator reumatoide e o desenvolvimento de manifestações oculares. Conclusão: As manifestações oculares da Artrite Reumatoide correspondem à significativa parcela das manifestações extra-articulares. No entanto, não foram constatadas associação de risco entre autoanticorpos e tais manifestações. [au]

Background: Ocular involvement represents about 40% of extra-articular manifestations of Rheumatoid Arthritis, pointing to impairment in patients' quality of life. Anti-cyclic citrullinated peptide antibody and rheumatoid factor are serological markers to laboratorial diagnosis of disease. Objective: Identify main ocular manifestations of Rheumatoid Arthritis and its relationship between positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody, through a Systematic Review of literature. Methods: Systematic Review was conducted on database search, including: PubMed, Scopus, Web of Science and SciELO until January, 2018. Inclusion and exclusion criteria were applied and data of select studies were extracted and organized in tables and graphics. Methodological appraisal and statistical analysis, including meta-analyses, were performed. Selected studies were stored in software Endnote X8 student (Serial Number: 3151802521 e Product Key: L899B-8N8FJ-SX9JW-BEQ58-U9HCD). Statistical analyses were performed with Review Manager software version 5.3 (free software). Results: From 1,985 studies found by database search, four studies were selected and analyzed. Sicca syndrome and secondary Sjögren's syndrome represented about 50% of ocular manifestations. Meta-analyses applied in two studies demonstrated no statistical significative risk association between anti-cyclic citrullinated peptide and development of ocular manifestations. Conclusion: From extra-articular manifestations of Rheumatoid Arthritis, ocular manifestations correspond to a significative amount. Nevertheless, there were no statistical significative risk association between autoantibodies and these manifestations. [au]

Effects of nonsurgical periodontal therapy in patients with rheumatoid arthritis: a prospective before and after study / Efectos de la terapia periodontal no quirúrgica en pacientes con artritis reumatoide: estudio prospectivo de antes y después

Abstract Background: periodontal therapy has been suggested to have systemic effects. However, studies of periodontal therapy in rheumatoid arthritis patients have produced controversial results. Aim: To compare the effects of nonsurgical periodontal therapy on biochemical markers of rheumatoid arthritis and periodontal parameters in patients with and without rheumatoid arthritis. Methods: a prospective before-and-after study was conducted that included 21 participants without and 29 participants with rheumatoid arthritis. Periodontal parameters, Porphyromonas gingivalis detection, C-reactive protein, rheumatoid factor and anti-citrullinated protein antibodies were measured at baseline and three months after nonsurgical periodontal therapy and the changes were statistically assessed. Results: In general, both groups presented statistically significant improvement in periodontal parameters (p<0.05). There was an increase in the counts of P. gingivalis in both groups at three months. In addition, there was a reduction in levels of anti-citrullinated protein antibodies and rheumatoid factor in participants with rheumatoid arthritis. In contrast, C-reactive protein levels increased in both groups but were higher in the rheumatoid arthritis group. Periodontal parameters in rheumatoid arthritis participants under disease-modifying antirheumatic drugs presented a slightly higher improvement (p <0.05). Conclusions: Nonsurgical periodontal therapy has similar improvements in periodontal parameters in patients with and without rheumatoid arthritis. In addition, nonsurgical periodontal therapy may benefit serum levels of anti-citrullinated protein antibodies and rheumatoid factors in patients with rheumatoid arthritis. NCT04658615.

Resumen Antecedentes: se ha sugerido que la terapia periodontal tiene efectos sistémicos. Sin embargo, los estudios de la terapia periodontal en pacientes con artritis reumatoide han producido resultados controvertidos. Objetivo: comparar los efectos de la terapia periodontal no quirúrgica sobre los marcadores bioquímicos de la artritis reumatoide y los parámetros periodontales en pacientes con y sin artritis reumatoide. Métodos: se realizó un estudio prospectivo de antes y después que incluyó a 21 participantes sin artritis reumatoide y 29 participantes con artritis reumatoide. Se midieron los parámetros periodontales, detección de Porphyromonas gingivalis, proteína C reactiva, factor reumatoide y anticuerpos anti-proteína citrulinada al inicio del estudio y tres meses después de la terapia periodontal no quirúrgica y los cambios se evaluaron estadísticamente. Resultados: En general, ambos grupos presentaron mejoría estadísticamente significativa en los parámetros periodontales (p <0.05). Hubo un aumento en los recuentos de P. gingivalis en ambos grupos a los tres meses. Además, hubo una reducción en los niveles de anticuerpos anti-proteína citrulinada y factor reumatoide en participantes con artritis reumatoide. Por el contrario, los niveles de proteína C reactiva aumentaron en ambos grupos, pero fueron más altos en el grupo de artritis reumatoide. Los parámetros periodontales en los participantes con artritis reumatoide bajo fármacos antirreumáticos modificadores de la enfermedad presentaron una mejoría ligeramente mayor (p <0.05). Conclusiones: La terapia periodontal no quirúrgica tiene mejoras similares en los parámetros periodontales en pacientes con y sin artritis reumatoide. Además, la terapia periodontal no quirúrgica puede beneficiar los niveles séricos de anticuerpos anti-proteína citrulinada y factor reumatoide en pacientes con artritis reumatoide. NCT04658615.

Autoanticuerpos en pacientes con diagnóstico de COVID-19 y enfermedades reumáticas / Autoantibodies in Patients with Diagnosis of Covid-19 and Rheumatic Diseases

Introducción: La COVID-19 es una enfermedad que causa alteraciones del sistema inmunitario. Estas pueden afectar el perfil inmunológico de las enfermedades reumáticas. Objetivo: Identificar el comportamiento del perfil inmunológico de los pacientes con enfermedades reumáticas en los cuales se confirmó el diagnóstico de COVID-19. Métodos: Se realizó una investigación básica con elementos de investigación clínica de 116 pacientes con enfermedades reumáticas, según los criterios del American College of Rheumatology, diagnosticados con COVID-19 entre mayo y diciembre del 2020 y atendidos en unidades asistenciales de la ciudad de Riobamba en Ecuador. Se determinaron los valores del perfil inmunológico en relación con la enfermedad reumática de base en el momento del diagnóstico de la COVID-19, y transcurridos los 7, 15, 30 y 90 días del diagnóstico de la afectación respiratoria. Resultados: Se identificó aumento del factor reumatoide en el 76,31 por ciento de los casos con artritis reumatoide a los 30 días del diagnóstico de COVID-19. El 18,18 por ciento de los pacientes con espondiloartropatías presentó factor reumatoide positivo a partir de los 15 días del diagnóstico de la enfermedad respiratoria. Aumentaron los pacientes con lupus y consumo de complemento y pacientes con síndrome de Sjögren y positividad de anti-SSa (61,54 por ciento ) y anti-SSb (41,15 por ciento ). Conclusiones: La COVID-19 causa cambios en el perfil inmunológico de los pacientes con enfermedades reumáticas: positividad de anticuerpos y consumo de complemento, y evoluciona de manera irregular en la positividad del factor reumatoide en pacientes con espondiloartropatías. La mayoría de las alteraciones inmunitarias se mantienen hasta 90 días después del diagnóstico de la COVID-19(AU)

Introduction: COVID-19 is a disease that generates alterations of the immune system. These can affect the immune profile of rheumatic diseases. Objective: To identify the behavior of the immunological profile of patients with rheumatic diseases in whom the diagnosis of COVID-19 was confirmed. Methodology: A basic research was carried out including elements of clinical research. Universe made up of 116 patients with rheumatic diseases, according to the criteria of the American College of Rheumatology, and COVID-19. Immunological profile values ―were determined in relation to the underlying rheumatic disease at the time of diagnosis of COVID-19, and after 7, 15, 30 and 90 days after the diagnosis of respiratory involvement. Results: An increase in rheumatoid factor was identified in up to 76.31 percent of the cases with rheumatoid arthritis 30 days after diagnosis of COVID-19. 18.18 percent of the patients with spondyloarthropathies presented positive RF after 15 days of diagnosis of the respiratory disease. There was an increase in patients with lupus and supplement consumption and patients with Sjögren's syndrome and positivity of anti-SSa (61.54 percent) and anti-SSb (41.15 percent). Conclusions: COVID-19 generates changes in the immunological profile of patients with RD due to antibody positivity and complement consumption; even behaving irregularly in the case of RF positivity in patients with AD. Most immune alterations persist for up to 90 days after COVID-19 diagnosis(AU)

Markers of Inflammation in Rheumatoid Arthritis and Osteoarthritis

Introduction: Rheumatoid arthritis is characterized by local and systemic effects of inflammation while osteoarthritis is aninflammatory degenerative disorder of joints. A wide range of inflammatory markers are implicated in pathogenesis of rheumatoidarthritis and osteoarthritis as a consequence of persistent imbalance between pro- and anti-inflammatory immune mechanisms,leading to chronic inflammation. Hence the present study is an attempt to estimate the levels of serum ceruloplasmin , C-reactiveprotein (CRP) and rheumatoid factor (RF) factor as inflammatory markers in serum of rheumatoid arthritis and osteoarthritispatients and compare them with normal healthy controls. Materials and Methods: Serum ceruloplasmin was estimated byspectrophotometric method while serum C-reactive protein and RA factor were detected using agglutination test in thirty patientsof rheumatoid arthritis ,osteoarthritis and age and sex matched healthy controls each were included in the study. Results:Significant increase in ceruloplasmin was observed (p<0.0001) in rheumatoid arthritis and osteoarthritis as compared to healthycontrols and in that especially ceruloplasmin was more elevated in rheumatoid arthritis than osteoarthritis. C-reactive proteinwas found to be positive in rheumatoid arthritis and osteoarthritis and none of the controls. RF factor was found positive inrheumatoid arthritis and none of the osteoarthritis and controls. Conclusion: There was increased level of serum ceruloplasmin inthe patients with rheumatoid arthritis and osteoarthritis. C-reactive protein and RF factor was found to be positive in rheumatoidarthritis while C-reactive protein was found to be positive in rheumatoid arthritis and osteoarthritis. These findings suggest apossible role of these inflammatory markers in the pathogenesis of rheumatoid arthritis.

Rheumatoid factor versus anti - cyclic citrullinated peptide antibody as screening tool for rheumatoid arthritis in an ophthalmic clinic

Patients with moderate to severe dry eyes are often screened at the Dry Eye Clinic to rule out connective tissue diseases. Rheumatoid factor (RF) is one of the screening tools to rule out rheumatoid arthritis (RA). Patients who turn out positive for the RF are often subjected to anti-CCP antibody evaluation for confirmation of disease. This article tries to highlight 3 cases of negative and anti-CCP antibody positive cases which presented to the ophthalmic clinic, unaware of their systemic status. Though RF is the cheapest modality to screen for RA, it is not always a reliable marker. One should order anti-CCP antibody for patients where suspicion is high, despite RF being normal.

Total knee arthroplasty for rheumatoid arthritis: Knee function and biochemical index changes / 中国组织工程研究

BACKGROUND: Previous studies on the clinical efficacy of total knee arthroplasty in the treatment of rheumatoid arthritis have been reported, but the effects of total knee arthroplasty on joint function and related biochemical parameters in patients with rheumatoid arthritis are little reported. Thereafter, more clinical evidence is needed. OBJECTIVE: To analyze the effect of total knee arthroplasty on joint function and related biochemical indicators in patients with rheumatoid arthritis. METHODS: Clinical data of 64 patients with 64 knees who underwent total knee arthroplasty were retrospectively analyzed. Comparative analysis of Hospital for Special Surgery, range of motion of the knee joint and quality of life scores before and 1 year after surgery was conducted. Changes of biochemical indicators such as C-reactive protein, rheumatoid factor and erythrocyte sedimentation rate were detected. The incidence of complications at 1 month after surgery was recorded. The study was approved by the Ethical Committee of Changzhou Traditional Chinese Medicine Hospital, and all patients signed the informed consents. RESULTS AND CONCLUSION: (1) Compared with the baseline levels, the Hospital for Special Surgery score, range of motion of the knee joint and quality of life scores at 1 year after surgery was significantly increased (P < 0.01), and the levels of C-reactive protein, rheumatoid factor and erythrocyte sedimentation rate were significantly decreased (P < 0.01). (2) One patient developed infection and two patients developed deep vein thrombosis of the lower extremity, which was relieved after symptomatic treatment. These results imply that total knee arthroplasty has a good clinical effect on rheumatoid arthritis, which can improve knee function and reduce the levels of C-reactive protein, rheumatoid factor and erythrocyte sedimentation rate, and has good safety.

Clinical and laboratory characteristics of rheumatoid arthritis with positive antinuclear antibody / 北京大学学报(医学版)

OBJECTIVE@#To analyse the clinical and laboratory characteristics of antinuclear antibody (ANA) positive rheumatoid arthritis (RA) patients.@*METHODS@#The clinical and laboratory data of 428 RA cases from Department of of Rheumatology and Immunology Peking University Third Hospital from Jan 2013 to Dec 2018 were collected and used to analyse characters between ANA positive group and ANA negative group. T test was used for the quantitative data in accordance with normal distribution. Wilcoxon rank sum test was used for the quantitative data of non normal distribution. The qualitative data were analyzed by chi square test. But while 1≤theoretical frequency < 5, chi square test of corrected four grid table was used. And Fisher exact probability method was used when theoretical frequency < 1.@*RESULTS@#The number of ANA positive group was 231 (54%). The female rate was obviously higher in ANA positive group (82.7% vs. 63.5%, χ2=20.355, P < 0.01). The rate of metatarsophalangeal joints (MTPJs) involvement was lower in ANA positive group (22.1%) than in ANA negative group (33.0) (χ2=6.414, P < 0.05). The incidence of secondary Sjögren's syndrome (sSS) was much higher in ANA positive group(19.5% vs. 4.1%, χ2=23.300, P < 0.01). The positivity of rheumatoid factor (RF), as well as the positivity of anti-cyclic citrullinated peptide(CCP) antibody was much higher in ANA positive group (77.1% vs. 53.8%, χ2=25.743, P < 0.01, 74.9% vs. 59.4%, χ2=11.694, P < 0.01, respectively). The levels of immunoglobulin G (IgG) and immunoglobulin M (IgM) of ANA positive group were higher [(15.1±5.1) g/L vs. (13.8±5.3) g/L, t=2.359, P < 0.05, 1.25 (0.92) g/L vs. 1.05 (0.65) g/L, Z=-3.449, P < 0.01, respectively]. But the levels of hemoglobin (Hb) and platelet (PLT) was lower in ANA positive group[(109.64±17.98) vs. (114.47±18.48) g/L, t=-2.734, P < 0.01; (266.4×109±104.6×109) vs. (295.9×109±100.1×109) /L, t=-2.970, P < 0.01, respectively].@*CONCLUSION@#The incidence of sSS was obviously higher in ANA positive group than in ANA negative group. Serum IgG of ANA positive group was higher, but Hb and PLT were lower.

A Study of Ophthalmological Manifestations of Rheumatoid Arthritis in Eastern India

Introduction: Patients with rheumatoid arthritis (RA) who are positive for anti-cyclic citrullinated peptide (CCP)/rheumatoidfactor (RF) have more extra-articular manifestations.Purpose: We tried to evaluate the magnitude of ocular manifestations in RA patients and to find out whether there is anycorrelation of anti-CCP or RF or disease duration to ocular involvement.Materials and Methods: A total of 288 patients diagnosed as RA with ocular symptoms were evaluated. Drug-induced effectsand cataract were excluded from the study.Results: About 18.1% were male and 81.9% were female. The minimum age was 21 and the maximum was 80 years. Theaverage age was 45.66 years. About 36.8% of patients had ocular manifestations. They were bilateral in 66% of patients.Multiple ocular manifestations were shown in 60.4% of patients. Dry eye was observed in 30.5%, anterior uveitis in 6.25%, andepiscleritis and scleritis in 7.6% each. Anti-CCP was present in 86.8% and RF in 78.5% of patients. The duration of diseasewas found to be statistically significant with respect to the presentation of ocular manifestations. Anti-CCP was found to bestatistically significant with respect to ocular manifestations but statistically insignificant in case of RF. No statistical significancewas found between gender and ocular manifestations.Conclusion: So far, no published Indian study with such large number of patients looked at ocular manifestations of RA correlatingwith disease duration and impact of both anti-CCP and RF at the same time. Our study indicates that patients suffering fromRA with anti-CCP positivity and long duration of disease should be evaluated ophthalmologically.

Salivary rheumatoid factor in primary and secondary Sjögren's syndrome / Factor reumatoide salival en síndrome de Sjögren primario y secundario

Sjögren's syndrome is a chronic autoimmune disease, characterized by the presence of hyposalivation and xerophthalmia, which in addition to other factors is diagnosed by the presence of rheumatoid factor in blood. The objective of the present study is to evaluate the presence of rheumatoid factor (IgG-IgM) in the saliva of patients with primary and secondary Sjögren's syndrome. Materials and methods: Forty samples from patients with primary and secondary Sjögren's syndrome previously diagnosed by the Arthritis and Rheumatism Specialist Center of the Autonomous University of Nuevo Leon were analyzed. Samples were taken from the saliva using the Carlson-Crittenden device to evaluate the IgG-IgM immunocomplex using the ELISA method. Results: No significant difference was found between the presence of IgM in primary (0.099±0.016) and secondary Sjögren syndrome (0.098±0.017), however, a high presence of IgG was found in the group of patients with secondary Sjögren's syndrome (0.134±0.054). Conclusion: The search for diagnostic tools using salivary biomarkers has come with economic and clinical advantages, however, in the present study no significant changes were found in salivary rheumatoid factor between both groups.

El síndrome de Sjögren es una enfermedad autoinmune crónica, caracterizada por la presencia de hiposalivación y xeroftalmia, la cual además de otros factores es diagnosticada por la presencia del factor reumatoide en sangre. El objetivo del presente estudio es evaluar la presencia del factor reumatoide (IgG-IgM) en saliva parotídea de pacientes con síndrome de Sjögren primario y secundario. Materiales y métodos: Se analizaron 40 muestras de pacientes con síndrome de Sjögren primario y secundario previamente diagnosticados por el Centro de Especialistas en Artritis y Reumatismo de la Universidad Autónoma de Nuevo León, a los cuales se les tomó una muestra de saliva parotídea mediante el dispositivo Carlson-Crittenden para evaluar mediante el método ELISA el inmunocomplejo IgG-IgM. Resultados: No se encontró diferencia significativa entre la presencia de IgM en el síndrome de Sjögren primario (0.099±0.016) y secundario (0,098±0,017), sin embargo en cuanto a la presencia de la IgG se encontró elevada en el grupo de pacientes con síndrome de Sjögren secundario (0,134±0,054). Conclusión: La búsqueda de herramientas diagnósticas mediante biomarcadores salivales ha traído consigo ventajas económicas y clínicas, sin embargo en el presente estudio no se encontró un cambio significativo en el factor reumatoide salival entre ambos grupos.

Artropatía relacionada con hepatitis C / Hepatitis C-related arthropathy

Resumen: OBJETIVO: Reportar una serie de casos de artropatía relacionada con hepatitis C. MATERIAL Y MÉTODO: Estudio retrospectivo en el que de enero de 2015 a diciembre de 2017 se incluyeron pacientes con infección crónica por VHC y artropatía referidos a la consulta de reumatología. Se examinaron de manera retrospectiva factores de riesgo, factor reumatoide (FR), anticuerpo contra péptido cíclico citrulinado (anti-PCC), anticuerpos contra VHC, genotipo viral y enzimas. También se determinó la subclase de artropatía, existencia de erosiones y tratamiento. Se excluyeron los pacientes infectados con VHB. RESULTADOS: Se incluyeron 31 pacientes. Los factores de riesgo de infección por VHC se identificaron solamente en 28 casos, que incluyen transfusión sanguínea antes de 1992 (n = 12) o abuso de drogas intravenosas (n = 16). En seis casos coexistieron artritis reumatoide y VHC; todos fueron seropositivos a factor reumatoide y anti-PCC y tres casos mostraron erosiones. Nueve casos tuvieron poliartritis simétrica u oligoartritis no erosiva que semejaba artritis reumatoide y 16 casos tuvieron artralgias simples. En total, el factor reumatoide fue positivo en 77% y las enzimas estuvieron altas en seis casos. La combinación de sulfasalazina, cloroquina y prednisona a dosis bajas y antiinflamatorios fue comúnmente indicada. CONCLUSIÓN: Los pacientes con infección por VHC pueden padecer artralgias-artritis. El tipo de artropatía debe diferenciarse por la hepatotoxicidad de los fármacos modificadores de enfermedad. El anti-PCC es útil para distinguir artropatía relacionada con hepatitis C de artritis reumatoide.

Abstract: OBJECTIVE: To report a case series of HCV-related arthropathy. MATERIAL AND METHOD: A retrospective study was done from January 2015 to December 2017 with patients with chronic HCV infection and arthropathy referred to our rheumatology clinic. All the patients were retrospectively reviewed. Risk factors for HCV infection including blood transfusion or intravenous drug abuse, rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP), anti-HCV (ELISA), viral genotype, and enzymes levels were examined. The clinical presentation of joint involvement, erosions, and type of treatment were also studied. Patients seropositive to HBV were excluded. RESULTS: There were included 31 patients. Risk factors were identified in only 28 cases, including blood transfusion (12) before 1992 and intravenous drug abuse (16). Rheumatoid arthritis coexisting with hepatitis C was found in 6 cases; all of these had anti-CCP, RF and erosions in 3. Nine patients gave a history of mild, symmetric poliar- thritis or oligoarthritis no-erosive resembling classic rheumatoid arthritis. Sixteen patients presented polyarthralgias. In total, RF was present in 77% out of 31 patients. Elevated enzymes were seen in 6 cases. Sulphasalazine, chloroquine, low dose prednisone and NSAIDs were commonly prescribed. CONCLUSION: The patients with HCV infection can present arthralgias/arthritis. The type of arthropathy must be differentiated due to the hepatotoxicity of disease modifying drugs. Anti-PCC antibody is useful for distinguishing HCV-related arthropathy from rheumatoid arthritis.

Importance of Synovial Biopsy of Knee Joint in the Diagnosis of Various Joint Disorders

Background: Rheumatoid arthritis hardly causes diagnostic problems when presented typically. Generally, difficulties arise when atypical clinical presentation is related with non-contributory preliminary investigations. Arthritis is an important cause of morbidity. Methods: In this study 60 total numbers of cases were included. This study was conducted in the Department of Orthopedics in K M Medical College & Hospital, Mathura. The duration of study was over a period of one year. Result: This result revealed that 40% cases were suffering from Chronic non -specific synovitis, 31.6% Rheumatoid arthritis, 6.7% Septic Arthritis & Osteoarthritis, 5% Gout & Synovial (osteo) chondro mitosis,3.3% Synovial sarcoma, 1.6% Giant cell tumor of tendon sheath Conclusion: This study concludes that Diagnostic method like immune-histological methods can be used to eliminate the “non-specificity”. It is also useful in achieving a better specific diagnosis.

Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis

Abstract Rheumatoid arthritis (RA) is an autoimmune/inflammatory disease affecting 0.5 to 1% of adults worldwide and frequently leads to joint destruction and disability. Early diagnosis and early and effective therapy may prevent joint damage and lead to better long-term results. Therefore, reliable biomarkers and outcome measures are needed. Refinement of the understanding of molecular pathways involved in disease pathogenesis have been achieved by combining knowledge on RA-associated genes, environmental factors and the presence of serological elements. The presence of autoantibodies is a distinctive feature of RA. Rheumatoid Factor and Anti-Citrullinated Protein Antibodies are the two most remarkable autoantibodies in RA and provide different clinical and pathophysiological information. They precede the onset of disease symptoms and predict a more severe disease course, indicating a pathogenetic role in RA. Therefore, they promote a more accurate prognosis and contribute for a better disease management. Several RA-associated autoantibody systems have been identified: Anti-Carbamylated Antibodies, Anti-BRAF, Anti-Acetylated, Anti-PAD4 antibodies and others. Hopefully, the characterization of a comprehensive array of novel autoantibody systems in RA will provide unique pathogenic insights of relevance for the development of diagnostic and prognostic approaches compatible with an effective personalized medicine.

Analyses of the Proficiency Testing Program and the Performance of Qualitative Reagents for Rheumatoid Factor / 임상검사와정도관리

BACKGROUND: Rheumatoid factor (RF) is used as one of the diagnostic criteria for rheumatoid arthritis. The purpose of this study was to evaluate qualitative RF reagents used in clinical laboratories in Korea, and to provide basic data that can be used as a reference to improve the quality of RF testing. METHODS: We reviewed the proficiency testing results for RF from the Korean Association of External Quality Assessment Service (KEQAS) and College of American Pathologists. Moreover, we evaluated five commercially available RF qualitative reagents, including LabSlide RF (IVD Lab Co., Korea), ASAN RA Latex Reagents (Asan Pharmaceuticals Co., Korea), RaPET RF (Stanbio Laboratory, USA), RF Latex Test (Pulse Scientific Inc., Canada), and RF-100 (Teco Diagnostics, USA). Commercially available quality control materials, calibrators, and pooled sera were used in this study. The consistency of qualitative reagents and Kappa statistics were calculated based on the quantitative values of the quality control materials and the mixed sera. RESULTS: Up to 51.5% of high concentration samples were reported as negative in KEQAS. RF qualitative reagent test results were not consistent among reagent types. The consistency of the qualitative and quantitative test results was between 51% and 100%, and the kappa statistics varied depending on the reagent manufacturer. CONCLUSIONS: Measurement of RF qualitative reagents used in domestic clinical laboratories was not consistent with the quantitative values, and hence it is necessary to improve the consistency and verify the adequacy of the cut-off value.

Role of Salivary Immune Parameters in Patients With Primary Sjögren's Syndrome

BACKGROUND: Several factors, including clinical manifestations and laboratory data, have been used to evaluate the disease activity of Sjögren's syndrome (SS). We investigated saliva indicators of disease activity in primary SS patients. METHODS: We enrolled 138 Taiwanese patients with primary SS and 100 Taiwanese normal controls. Interleukin (IL)-6, IL-17A, tumor necrosis factor-alpha (TNF-α), and rheumatoid factor (RF)-IgA levels in saliva samples were measured using ELISA or fluorescent enzyme-linked immunoassay. Serum IgG, IgA, and IgM levels were measured by nephelometry. Erythrocyte sedimentation rate (ESR) was measured with an automatic ESR analyzer. The t-test and Pearson correlation test were used. RESULTS: IL-6 level was higher in primary SS patients than in normal controls (14.23±14.77 vs 9.87±7.32, P=0.012), but there were no significant differences in IL-17A, TNF-α, and RF-IgA levels. In primary SS patients, IL-6 level correlated weakly with ESR and IgG levels (r=0.252, P=0.015, and r=0.248, P=0.017, respectively), and TNF-α level correlated weakly with IgG level (r=0.231, P=0.024). CONCLUSIONS: IL-6 may play a role in SS pathogenesis. Saliva IL-6 might be an indicator of disease activity in primary SS patients.

Rheumatoid Factor Positivity is Associated with Lower Bone Mass in Korean Male Health Examinees without Clinically Apparent Arthritis

OBJECTIVE: This cross-sectional study aimed to investigate the association between rheumatoid factor (RF) positivity and bone mineral density (BMD) in male Korean subjects without any history of joint disease. METHODS: Of 84,344 males who had undergone a comprehensive health checkup program in 2012, 1,390 male health examinees were recruited, whose BMD and RF results were available. A RF titer ≥20 IU/mL was considered positive. BMD was measured at lumbar spine (L1~L4) or hip (femoral neck and total hip) by dual-energy X-ray absorptiometry. RESULTS: The association between RF positivity and BMD was assessed by multiple linear regression analysis. The mean age was 52.7±10.9 years (range 19~88 years), and RF was detected in 64 subjects (4.6%). Demographics and laboratory data were not different between RF-positive and -negative subjects except hepatitis B surface antigen (HBsAg), which was more frequently seen in RF-positive subjects (15.6% vs. 4.3%, p=0.001). RF-positive subjects had significantly lower BMD compared to RF-negative subjects in lumbar spine but not in total hip regardless of the existence of HBsAg (1.17±0.16 g/cm2 vs. 1.10±0.18 g/cm2, p=0.002 in total subjects; 1.17±0.16 g/cm2 vs. 1.10±0.18 g/cm2, p=0.004 in HBsAg-negative subjects). After adjusting for multiple confounders, RF positivity was negatively associated with lumbar spine BMD (B=−0.088 and standard error=0.035, p=0.011). CONCLUSION: Our results show that the presence of RF could have an unfavorable impact on bone density in apparently normal males. Additional studies to elucidate the osteoimmunological mechanism of rheumatoid factor are warranted.

Effect of Different Combinations of Gentianae Macrophyllae Radix on MMP-3 and TIMP-1 in Rheumatoid Arthritis Rats with Wind-cold-dampness Arthralgia / 中国实验方剂学杂志

Objective: To observe the effects of different combinations of Gentianae Macrophyllae Radix (Qinjiao) on the ankle joint matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) of rheumatoid arthritis (RA) model rats with wind-cold-dampness arthralgia.Method: Eighty healthy SD rats were randomly divided into 8 groups, namely blank control group, collage Ⅱ model group, wind-cold-dampness syndrome model group, positive control group, single-taste Gentianae Macrophyllae Radix group, Gentianae Macrophyllae Radix-Clematidis Radix et Rhizoma group (GC group), Gentianae Macrophyllae Radix-Taxilli Herba group (GT group), Gentianae Macrophyllae Radix-Stephanlae Tetrandrae Radix group (GS group), with 10 rats in each group. Rat model of wind-cold-dampness RA was induced through the injection with type Ⅱ collagen emulsion and wind-cold-dampness stimulation. After the establishment of the model, the blank control group, collage Ⅱ model group and wind-cold-dampness syndrome model group were given normal saline, and the corresponding liquid medicine was given to each administration group. In the experiment, the thickness of the left posterior metatarsal of rats was measured every 3 days, and the swelling degree of metatarsal was calculated. The arthritis index (AI) was evaluated on the 38th day of the experiment. The serum rheamatoid factor(RF) content of rats was detected by enzyme linked immunosorbent assay (ELISA). The expressions of MMP-3 and TIMP-1 in ankle joint were detected by Western blot. The expressions of MMP-3 and TIMP-1 mRNA in ankle joint were detected by real-time fluorescence quantitative PCR (Real-time PCR).Result: Compared with the blank group, the swelling degree, AI score, serum RF content, MMP-3 protein expression and MMP-3 mRNA expression in ankle joints of coll age Ⅱ model group and model wind-cold-dampness syndrome group were significantly increased (PPPPPPConclusion: For rheumatoid arthritis with wind-cold-dampness arthralgia, mild and warm traditional Chinese medicine (TCM) has a better effect than the combination of mild and cold TCM or mild TCM drugs. The experimental results are basically consistent with the principle of "treating cold diseases with hot medicine". The mechanism of the compatibility in treating rheumatoid arthritis due to wind-cold-dampness arthralgia may be related to the reduction of MMP-3, the increase of TIMP-1 expression and the reduction of articular cartilage damage.

Effect of Tripterygium glycosides combined with Recombinant human tumor necrosis factor receptorⅡ antibody fusion protein for injection on serum vascular endothelial growth factor, rheumatoid factor, receptor activator of nuclear factor κ B ligand levels in patients with rheumatoid arthritis / 中国综合临床

Objective To investigate the effect of tripterygium glycosides combined with recombinant human tumor necrosis factor receptor Ⅱ antibody fusion protein for injection on serum vascular endothelial growth factor (VEGF),rheumatoid factor (RF),receptor activator of nuclear factor κ B ligand (RANKL) levels in patients with rheumatoid arthritis.To provide reference for rational clinical application.Methods From December 2014 to January 2016,132 patients with rheumatoid arthritis were divided into observation group and control group by random number table method,,with 66 cases in each group,The control group was treated with tripterygium glycosides alone (10 mg each time,3 times daily,orally) for 3 months.The observation group was treated with a combination of tripterygium glycosides and recombinant human tumor necrosis factor receptor Ⅱ (0.4 mg/kg,once weekly,hypodermic injection) for 3 months.The clinical efficacy,and serum VEGF,RF and RANKL levels were compared between 2 groups.Results The effective rate of the observation group was 92.4％ (61/66),which was significantly higher than that in the control group (80.3％,53/66).There was a significant difference between the two groups (x2=4.117,P＜0.05).There was no significant difference in the levels of serum VEGF,RF and RANKL between the two groups (t =0.174,0.103,0.359,all P＞0.05).After treatment,the levels of serum VEGF,RF and RANKL in the observation group and the control group were (20.8± 11.5) ng/L and (27.3 ±13.1) ng/L,(258.4±54.5) U/L and (298.1 ±49.5) U/L,(0.083±0.021) pmol/L and (0.197 ± ±0.064),respectively.There were significant differences between the two groups (t =3.029,4.381,13.750,all P＜0.05).The incidence rate of adverse reactions in the control group was 10.5％ (7/66),which was significantly higher than that in the observation group (1.5％,1/66).There was a significant difference between the two groups(x2 =4.790,P＜0.05).The one-year recurrence rate was 25.0％ (13/52) in the control group and that was 6.7％ (4/60) in the observation group,respectively,and there was a significant difference between the two groups (x2 =7.272,P＜ 0.05).Conclusion Tripterygium glycosidescombined with recombinant human tumor necrosis factor receptor Ⅱ antibody fusion protein for injection is effective in the treatment of rheumatoid arthritis,which reduces the levels of serum VEGF,RF and RANKL,and has a low incidence of adverse reactions and recurrence.

Study of Prognostic Significance of Anti Cyclic Citrullinated Peptide Antibodies in Patients with Rheumatoid Arthritis

Background: Rheumatoid arthritis is a chronic autoimmune inflammatory disease with articular and extra-articular manifestation that affects 0.5 to 1 % of total population. Aim and Objectives: To correlate Rheumatoid factor (RF) and Anti-CCP antibody in RA, to evaluate prognostic value of RF and Anti-CCP antibody in RA. Materials and methods: Retrospective study of total 50 patients admitted to our hospital from January 2018 to December 2018 was done. All patients were diagnosed as rheumatoid arthritis as per diagnostic criteria of American College of Rheumatology. All patients had symptom duration of at least one Year. Anti-CCP and lgM-RF were evaluated in all patients. Disease activity score 28 was calculated in all patients. Radiological Damage was assessed by Larsen Score. Results: Anti-CCP and RF were significantly correlated with each other and both were seen as significant independent predictors of radiological outcomes (p value 0.01 and <0.05 respectively). Combination of these two had highest risk for erosive joint damage. Conclusion: RA is more common in female. Anti-CCP antibody and RF both in combination were associated with higher probabilities of erosive disease.